NCT07677566尚未招募4 期
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- pCR + MRD
研究概览
简要总结
The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy. The main questions it aims to answer are:
Does this combination treatment improve the pathological complete response rate (pCR)? What is the minimal residual disease (MRD) rate in these patients? What are the safety profiles and any adverse effects associated with this treatment? Researchers will compare the combination of darolutamide and 177Lu-PSMA-617 to a placebo to see if the combination is effective in treating high-risk localized prostate cancer.
Participants will:
Receive either darolutamide combined with 177Lu-PSMA-617 or a placebo every day for 12 weeks.
Visit the clinic every 6 weeks for checkups and tests. Keep a diary of their symptoms and any side effects experienced during the treatment.
Undergo imaging tests, including prostate MRI and PSMA PET/CT, before surgery and during follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must be ≥ 18 and ≤75 years of age
- •All patients must have a histologically or cytologically diagnosis of prostate cancer，without distant metastasis, and suitable for radical prostatectomy
- •All patients meet at least one of the following criteria： multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor ≥ T2c； Gleason score of primary tumor ≥ 8； prostate specific antigen (PSA) ≥20 ng/ml； Radiographic assessment of regional lymph node metastases (N1)
- •Eastern Cooperative Oncology Group (ECOG) physical condition score 0- 1
- •Primary lesion SUVmax ≥ 20.0 as assessed by PSMA-PET examination.
- •Adequate organ function: Complete Blood Count: White blood cell count (WBC) ≥ 3.0 × 10^9/L, platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 9 g/dL. Renal Function: Serum creatinine ≤ 2 × ULN. Liver Function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, total bilirubin (TBIL) ≤ 1.5 × ULN. Coagulation Function: International normalized ratio (INR) < 1.
- •Voluntary Participation: Participants must voluntarily agree to participate and sign the informed consent form (ICF), indicating their understanding of the purpose of the study and the required procedures, as well as their willingness to participate in the research. Participants must be willing to comply with the prohibitions and restrictions outlined in the study protocol.
- •Patients of childbearing potential must be willing to take high-efficiency contraceptive measures during the study period and within 120 days after the last dose of treatment
排除标准
- •Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are not eligible
- •Patients with low-risk and medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: prostate specific antigen (PSA) <20 ng/mL multiparameter MRI or PSMA PET / CT shows clinical staging of primary tumor < T3, Gleason score of primary tumor < 8
- •Patients with clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases (any M1）
- •Primary lesion SUVmax < 20.0 as assessed by PSMA-PET examination.
- •Patients who have previously received androgen deprivation therapy (medical or surgical) more than 3 months or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy
- •Patients with severe or uncontrolled concurrent infections
- •Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration
- •Uncontrolled severe hypertension, persistently uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection
- •Patients with a history of other malignancies within the past 5 years, except for prostate cancer, are not eligible; however, cured basal cell carcinoma or squamous cell carcinoma of the skin may be eligible
- •Patients with mental illness, mental disability, or inability to provide informed consent
结局指标
主要结局
pCR + MRD
时间窗: Screening, End of Neoadjuvant Treatment( 12 weeks after baseline)
pCR + MRD (pCR: Pathological Complete Response; Minimal Residual Disease (MRD) rate: defined as the proportion of patients achieving MRD among all patients; MRD is defined as postoperative pathology indicating that the longest diameter of the tumor is ≤ 5 mm)
次要结局
- Patient Sexual Function(Day 1 of Cycle 1&2 ( each cycle is 6 weeks), 1 month after treatment, 3 and 6 months after treatment, 6 months until 2 years)
- PSA Response Rate (defined as a decrease in PSA of 50% or more)(Day 1 of Cycle 1&2 (each cycle is 6 weeks), End of Neoadjuvant Treatment (12 weeks after baseline). The last week of each month for the first 3 months after the periprocedural, thereafter the last week of every 3rd month for a total duration of 1 year)
- PSMA Response Rate(Screening, End of Neoadjuvant Treatment (12 weeks after baseline))
- 1-year biochemical recurrence-free survival, bRFS(The last week of each month for the first 3 months after the periprocedural, thereafter the last week of every 3rd month for a total duration of 1 year)
- Perioperative Complications(Perioperative Period)
- Patient Quality of Life(Day 1 of Cycle 1&2 ( each cycle is 6 weeks), 1 month after treatment, 3 and 6 months after treatmnet,6 months until 2 years)
- Tumor Radiation Absorbed Dose: The maximum absorbed dose of 177Lu-PSMA-617 treatment for the prostate (measured in Gray [Gy])(Screening, End of Neoadjuvant Treatment(12 weeks after baseline))
研究者
Hongqian Guo
Director
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
研究点 (1)
Loading locations...
相似试验
招募中
3 期
An open study for participants who have been on darolutamide treatment in any other Bayer studyCancer2022-502084-38-00Bayer Consumer Care AG, Bayer AG258
招募中
2 期
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial2024-512132-29-00Swiss Group for Clinical Cancer Research100
尚未招募
2 期
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaLocally Advanced Sinonasal CarcinomaNCT07645846Sun Yat-sen University23
尚未招募
2 期
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADTHigh-Risk Localized Prostate CancerNCT07550517Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60
招募中
不适用
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT TreatmentNon-metastatic Castration-resistant Prostate CancerNCT07538843Bayer800